The efficacy of cholesterol-lowering drug therapy in primary and secondary prevention has been firmly established. The combined results of 9 large long-term statin trials (including the ALLHAT-LLT) showed a 27% reduction in coronary heart disease (CHD) events and a 14% reduction in all-cause mortality. [1] [2] [3] [4] [5] [6] [7] [8] [9] These reductions, however, were average effects of statin therapy for all patients included in the trials. Pharmacogenetic findings suggest that patients may differ in their response to statins because of their genetic constitution. 10 The angiotensin-converting enzyme (ACE) is thought to play an important role in the development of coronary artery disease. Plasma and cellular levels of ACE are associated with a large insertion-deletion (ID) polymorphism located in intron 16 of the ACE gene. DD carriers have about twice the plasma levels of ACE compared with II carriers, whereas heterozygotes have intermediate levels. 11 In a meta-analysis including 145 reports with an overall sample size of 49 959, the excess risk in subjects with the DD genotype compared with subjects with the II genotype was 32% for coronary heart disease (30 studies) and 45% for myocardial infarction (MI) (20 studies). 12 Contradictory results have been published on the influence of the ACE ID polymorphism on the effec- tiveness of statins. In the CARE trial, no effect was found for the ACE ID polymorphism alone on the efficacy of pravastatin in reducing the primary end point. 13 In the LCAS study, subjects with the ACE DD genotype had the strongest reduction of coronary atherosclerosis with pravastatin. However, the distribution of clinical events among genotypes was not significantly different. 14 In an observational cohort study among subjects with hypercholesterolemia the beneficial effect of statins on coronary heart disease was different for men with different ACE genotypes. In men with 2 I alleles, the largest beneficial effects of statins were demonstrated, whereas in men with 2 D alleles, no beneficial effects were demonstrated. 15 The objective of this study was to determine whether the ACE ID polymorphism interacts with pravastatin to modify the risk of CHD and other cardiovascular end points in a large randomized clinical trial of high-risk individuals.
Methods

Study Population and Design
GenHAT is an ancillary study of the ALLHAT. The LLT component of ALLHAT was designed to evaluate the impact of large sustained cholesterol reductions on all-cause mortality in a hypertensive cohort with at least 1 other CHD risk factor and to assess CHD reduction and other benefits in populations that had been excluded or underrepresented in previous trials, particularly older persons, women, racial and ethnic minority groups, and persons with diabetes. A priori secondary outcomes included a combination of CHD death (fatal CHD, coronary revascularization-related mortality, previous angina or MI and no known potentially lethal noncoronary disease process) and nonfatal MI, cardiovascular disease (CVD) mortality (mortality due to CHD, stroke, other treated angina, heart failure, peripheral disease), CHD (CHD death, coronary revascularization, hospitalized angina), fatal stroke, other CVD, non-CVD mortality, stroke (fatal and nonfatal), and heart failure. The design of ALLHAT, including the LLT, and its participant and clinical site recruitment and selection have been reported elsewhere. 9, [16] [17] [18] Briefly, ALLHAT-LLT was a randomized, nonblinded, large simple trial conducted from 
Statistical methods
Participants were stratified according to genotype, and baseline characteristics were compared using v 2 and t tests. The efficacy of pravastatin in reducing the risk of the primary outcome (all-cause mortality) and of a priori secondary outcomes is compared between the genotype strata (II + ID vs DD), using an interaction term in the Cox proportional hazards model. These analyses were adjusted for the following potential confounding baseline factors: sex (men/women), race (black/white), current smoking status (yes/no), history of diabetes (yes/no), history of CHD (yes/no), visit 1 systolic blood pressure (mm Hg), and age (years). Because of our previous finding that the interaction between the ACE ID polymorphism and effectiveness of statins may be modified by sex, 19 a 3-way interaction for sex-ACE genotype-statin therapy was included in the model to compare the interaction between men and women. We also included a 3-way interaction for race-ACE genotype-statin therapy in the model to examine whether ethnicity accounted for differences in the pharmacogenetic effect of the ACE ID genotype on the primary and secondary outcomes.
Results
The genotyped population in the lipid-lowering arm of ALLHAT included 9467 participants. Of these, 4741 4Adjusted for treatment group (pravastatin/usual care), sex (male/female), race (black/white), and 8 baseline variables: current smoking status (yes/no), history of diabetes (yes/ no), history of CHD (yes/no), systolic blood pressure level (mm Hg), and age (years). yP = .047. zP = .038.
were in the pravastatin treatment group and 4726 were in the usual care group. In Table I , baseline characteristics according to ACE ID genotype for subjects randomized to pravastatin and subjects in the usual care group are shown. The proportions and characteristics within each of the 3 genotypes assigned to each treatment (pravastatin vs usual care) were well balanced.
The total number of trial events and the cumulative 6-year Kaplan-Meier event rates of clinical outcomes by ACE genotype and treatment are shown in Table II . The effects of ACE ID on the clinical outcomes (regardless of pravastatin treatment assignment) can be found in Table III . Subjects with the ID genotype had a statistically significant lower risk of fatal and nonfatal stroke compared with subjects with the II genotype (adjusted hazard ratio [HR adj ] 0.76, 95% CI 0.59-0.99). This finding was marginally significant for fatal strokes alone ( P = .051).
Hazard ratios of the effect of statin use are shown, by genotype, in Table IV . Three-way analyses of the ACE ID genotypes, treatment, and primary clinical outcome (all-cause mortality) identified no differences in the efficacy of pravastatin between subjects with the II and DD genotypes (interaction HR [IHR] 0.81, 95% CI 0.58-1.14, P = .31), or between subjects with the ID and DD genotypes (IHR 0.90, 95% CI 0.69-1.17, P = .42) ( Table IV) . The secondary end points were consistent with these negative findings. No significant gene-drug interactions were found. We evaluated gene-drug interactions in relation to the primary and secondary outcomes in subgroups based on sex and on race. There were no apparent gene-treatment interactions across sex-gene-drug or race-gene-drug subgroups (data not shown).
Discussion
The GenHAT-LLT study is a large pharmacogenetic trial of pravastatin versus usual care. Based on genotype data collected from almost 10 000 individuals, who were followed for cardiovascular events using standard, well-defined definitions for cardiovascular outcomes, we found no compelling evidence that ACE ID genotype is a major determinant of the efficacy of pravastatin in reducing the risk of cardiovascular events. We did not find any significant interactions in the response to therapy, despite the large number of tests performed. We did observe that participants with the II and ID genotypes tended to fare better on pravastatin than usual care for most of the outcomes examined, whereas the opposite was true for the DD participants. The II versus DD and the ID versus DD interaction hazard ratios were b1.00 for all outcomes except heart failure, ranging from 0.47 for fatal strokes (II vs DD) to 0.98 for CHD (ID vs DD). This is in concordance with what would be expected based on a previous study. 15 The GenHAT study selected individuals based on preexisting coronary risk factors and hypertension. Therefore, there is some uncertainty about the applicability of the findings of this study to the association in subjects without these risk factors.
In the ALLHAT study, no overall beneficial effect of pravastatin was demonstrated on the primary outcome. After 6 years of follow-up, 26% of subjects in the usual care arm used statins, and 16% in the pravastatin arm did not use a lipid-lowering drug anymore. There was no significant differential in crossovers among ACE genotypes and therefore would not affect the interaction between pravastatin and the ACE polymorphism. Our finding that the ACE ID polymorphism did not modify the efficacy of statins was in concordance with 3 studies. 13, 14, 19 Results were different from the results of the Rotterdam study that found a significant interaction in men. 15 Although no statistically significant interaction was found in GenHAT, there was a trend toward better efficacy in the subjects with the II and ID genotypes compared with the DD genotype. For example, subjects with the ID genotype tended to fare better on pravastatin than usual care for fatal CHD and nonfatal MI (HR adj 0.84, 95% CI 0.68-1.03), whereas there was no effect of pravastatin in subjects with the DD genotype (HR adj 0.99, 95% CI 0.77-1.27). This result is similar to the findings in the Rotterdam study. However, we did not find evidence that there were differences in efficacy between men and women as was found in the Rotterdam Study. The physiological role of the renin-angiotensin system varies with sodium intake, age, and disease status. 20 Because this trial included high-risk hypertensive patients, while the Rotterdam cohort study included a hypercholesterolemic subset of the general population, this might be an explanation for the different findings in men. A strength of the GenHAT study, however, is that it was performed in a large clinical trial with reasonable event rates in both subjects randomized to pravastatin and in subjects randomized to usual care. Furthermore, because only the ID polymorphism was studied, an effect of other polymorphisms in the ACE gene on pravastatin cannot be ruled out.
These pharmacogenetic analyses of the ALLHAT-LLT in combination with results from earlier studies provide no rationale for using ACE ID genotype to guide decisions about treatment with pravastatin. Because there was a trend toward less efficacy in subjects with the DD genotype, more research in larger settings, possibly combinations of different trials/cohort studies, is necessary.
